Drug intelligence / Profile preview

BRGP0811

Development stage: Preclinical
Lead developer: Berg
Modality: Small Molecules

Overview

BRGP0811 is an investigational drug candidate being developed by BPGbio (formerly Berg) for the treatment of Parkinson's disease. The compound was discovered using BPGbio's proprietary NAi Interrogative Biology® platform, an AI-driven system that analyzes multi-omics data from patient samples to identify novel therapeutic targets and biomarkers. BRGP0811 is designed to modulate a specific oxidoreductase target, a class of enzymes involved in biological redox reactions that play a critical role in mitochondrial function and oxidative stress—pathways frequently dysregulated in neurodegenerative disorders. The program is currently in the discovery and preclinical stage, part of BPGbio's broader neurology pipeline which also includes diagnostic tools like ParkinsonDx.

Beyond the preview

Go deeper on BRGP0811.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRGP0811.

Explore the full profile